Premium
Prioritizing migraine biomarkers research
Author(s) -
Gurwitz David,
Diamond Seymour
Publication year - 2007
Publication title -
drug development research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.582
H-Index - 60
eISSN - 1098-2299
pISSN - 0272-4391
DOI - 10.1002/ddr.20189
Subject(s) - migraine , chronic migraine , medicine , migraine disorders , migraine treatment , psychiatry , intensive care medicine
Migraine is among the most common chronic disorders in the developed countries, affecting up to 17% of adult women and 6% of adult men. It is also among the chronic disorders most commonly associated with recurring absence from work. It has been estimated that in the United States the indirect annual societal cost of migraine, mostly as lost work, is US$12 billion. Migraine diagnosis and treatment is hindered by the lack of reliable serum or genetic biomarkers that could potentially improve treatment choices. Research programs focused on identifying and developing migraine biomarkers for both prevention and treatment must be included in the national biomedical research agenda. Drug Dev Res 68:267–269, 2007. © 2007 Wiley‐Liss, Inc.